结外NK/T细胞淋巴瘤的风险评估与治疗进展  

Risk Assessment and Treatment Progress of Extranodal NK/T-Cell Lymphoma

作　　者：张逸云 张浩[1] ZHANG Yiyun;ZHANG Hao(Department of Otolaryngology,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200001,China)

机构地区：[1]上海交通大学医学院附属瑞金医院耳鼻咽喉科,上海200001

出　　处：《中国细胞生物学学报》2021年第9期1876-1881,共6页Chinese Journal of Cell Biology

摘　　要：结外NK/T细胞淋巴瘤(extranodal NK/T-cell lymphoma,ENKTCL)是非霍奇金淋巴瘤中一种少见的亚型,其发病机制包括EB病毒感染、ENKTCL相关基因异常、信号通路的异常活化、肿瘤微环境的改变,该病病程进展快,预后较差,预后模型包括Ann Arbor分期模型、国际预后指数(IPI)模型、韩国预后指数(KPI)模型、PINK-E模型、Nomogram风险指数(NRI)模型,同时临床上已发现越来越多ENKTCL的独立预后因素,这对于ENKTCL的风险评估有着积极意义。目前,ENKTCL的治疗方案包括放化疗治疗、造血干细胞移植治疗、靶向治疗。该文对ENKTCL的发病机制、预后模型、风险评估和治疗进展进行综述,以期提高ENKTCL的诊治效果。ENKTCL (extranodal NK/T-cell lymphoma) is a rare subtype of non-Hodgkin’s lymphoma.Its pathogenesis includes Epstein-Barr virus infection,ENKTCL-related gene abnormalities,abnormal activation of signal pathways,and change of tumor microenvironment.The disease develops rapidly with poor prognosis.Prognosis models include Ann Arbor staging model,IPI (international prognostic index) model,KPI (Korea prognostic index) model,PINK-E model and NRI (Nomogram risk index) model.Meanwhile,more and more independent prognostic factors of ENKTCL have been found in clinical research,which is of positive significance for risk assessment of ENKTCL.Current treatments include radiotherapy and chemotherapy,hematopoietic stem cell transplantation,and targeted therapy.This study reviews the pathogenesis,prognostic models,risk assessment and treatment progress of ENKTCL in order to improve its treatment effect.

关 键 词：ENKTCL 预后模型 风险评估 放化疗 

分 类 号：R733.1[医药卫生—肿瘤]